Skip to main content

Advertisement

SpringerLink
Log in

Hemodilution therapy using automated erythrocytapheresis in central retinal vein occlusion: results of a multicenter randomized controlled study

  • Retinal Disorders
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

Background

Central retinal vein occlusion (CRVO) leads to poor visual outcome in most eyes. Abnormal hemorheology was suspected to play a major role in its pathogenesis. CRVO treatment is still a matter of debate but several studies have pointed out the efficacy of isovolumic hemodilution. The aim of this study was to assess the feasibility and efficacy of hemodilution using automated erythrocytapheresis in recent-onset CRVO.

Methods

In this prospective randomized controlled multicenter study, 61 consecutive CRVO patients were enrolled when they met the following criteria: CRVO lasting for 3 weeks or less, visual acuity ranging from 20/200 to 20/32, age between 18 and 85 years, no diabetes, no uncontrolled systemic hypertension, no antiplatelet or anticoagulant therapy, hematocrit higher than 38%, and signed informed consent. Patients were randomly assigned to the hemodilution group (n = 31) or to the control group (n = 30). Hemodilution therapy consisted of one session of erythrocytapheresis on outpatient basis, followed by additional session(s) for 6 weeks if needed. Target hematocrit was 35%. Follow-up was 12 months.

Results

No statistical differences in age, associated risk factors, or CRVO characteristics were observed at baseline between both groups. Mean visual acuity was equivalent to 20/80 in the hemodilution group and to 20/63 in the control group (non-significant difference). In the treated group, mean number of hemodilution sessions was 3.3 (range, 1 to 6), and no major side-effects occurred. At the 12-month follow-up visit, 64.5% of the hemodilution group had visual acuity of 20/40 or better compared to 40% of the control group (p = .048). Visual change was a gain of 1.7 ETDRS line in the hemodilution group versus a loss of 2.3 lines in the control group (p = .007). There was less conversion into an ischemic form in the hemodilution group (11%) than in the control group (50%, p = .004). Mean final retinal thickness was 289 μm in the hemodilution group versus 401 μm in the control group (p = .068).

Conclusions

This multicenter controlled randomized study demonstrated that automated erythrocytapheresis is a safe and effective tool for performing hemodilution and confirmed that hemodilution therapy can improve the final prognosis of CRVO when applied in the early phase of the disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. The central vein occlusion study group (1997) Natural history and clinical management of central retinal vein occlusion. The central vein occlusion study group. Arch Ophthalmol 115: 486-491

    Google Scholar 

  2. Glacet-Bernard A, Coscas G, Chabanel A, Zourdani A, Lelong F, Samama MM (1996) Prognostic factors for retinal vein occlusion: prospective study of 175 cases. Ophthalmology 103:551–560

    PubMed  CAS  Google Scholar 

  3. The central vein occlusion study group (1995) A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion. The central vein occlusion study group N report. Ophthalmology 102: 1434-1444

    Google Scholar 

  4. Glacet-Bernard A, Coscas G, Chabanel A, Zourdani A, Lelong F, Samama MM (1994) A randomized, double-masked study on the treatment of retinal vein occlusion with troxerutin. Am J Ophthalmol 118:421–429

    PubMed  CAS  Google Scholar 

  5. Kohner EM, Laatikainen L, Oughton J (1983) The management of central retinal vein occlusion. Ophthalmology 90:484–487

    PubMed  CAS  Google Scholar 

  6. Glacet-Bernard A, Kuhn D, Vine AK, Oubraham H, Coscas G, Soubrane G (2000) Treatment of recent onset central retinal vein occlusion with intravitreal tissue plasminogen activator: a pilot study. Br J Ophthalmol 84:609–613

    Article  PubMed  CAS  Google Scholar 

  7. Hattenbach LO, Steinkamp G, Scharrer I, Ohrloff C (1998) Fibrinolytic therapy with low-dose recombinant tissue plasminogen activator in retinal vein occlusion. Ophthalmologica 212:394–398

    Article  PubMed  CAS  Google Scholar 

  8. Elman MJ, Raden RZ, Carrigan A (2001) Intravitreal injection of tissue plasminogen activator for central retinal vein occlusion. Trans Am Ophthalmol Soc 99:219–221, discussion 222–213

    PubMed  CAS  Google Scholar 

  9. Ip MS, Scott IU, VanVeldhuisen PC, Oden NL, Blodi BA, Fisher M, Singerman LJ, Tolentino M, Chan CK, Gonzalez VH (2009) A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs. Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol 127:1101–1114

    Article  PubMed  Google Scholar 

  10. Rouvas A, Petrou P, Vergados I, Pechtasides D, Liarakos V, Mitsopoulou M, Ladas I (2009) Intravitreal ranibizumab (Lucentis) for treatment of central retinal vein occlusion: a prospective study. Graefes Arch Clin Exp Ophthalmol 247:1609–1616

    Article  PubMed  CAS  Google Scholar 

  11. Gregori NZ, Gaitan J, Rosenfeld PJ, Puliafito CA, Feuer W, Flynn HW Jr, Berrocal AM, Al-Attar L, Dubovy S, Smiddy WE, Schwartz SG, Lee WH, Murray TG (2008) Long-term safety and efficacy of intravitreal bevacizumab (Avastin) for the management of central retinal vein occlusion. Retina 28:1325–1337

    Article  PubMed  Google Scholar 

  12. Spaide RF, Chang LK, Klancnik JM, Yannuzzi LA, Sorenson J, Slakter JS, Freund KB, Klein R (2009) Prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion. Am J Ophthalmol 147:298–306

    Article  PubMed  CAS  Google Scholar 

  13. Ferrara DC, Koizumi H, Spaide RF (2007) Early bevacizumab treatment of central retinal vein occlusion. Am J Ophthalmol 144:864–871

    Article  PubMed  CAS  Google Scholar 

  14. Jonas JB, Akkoyun I, Kamppeter B, Kreissig I, Degenring RF (2005) Intravitreal triamcinolone acetonide for treatment of central retinal vein occlusion. Eur J Ophthalmol 15:751–758

    PubMed  CAS  Google Scholar 

  15. Angulo Bocco MC, Glacet-Bernard A, Zourdani A, Coscas G, Soubrane G (2008) Injection intra-vitréenne: évaluation rétrospective de la technique et des complications d’une série de 2028 injections. J Fr Ophtalmol 31:693–698

    Article  PubMed  CAS  Google Scholar 

  16. Arend O, Remky A, Jung F, Kiesewetter H, Reim M, Wolf S (1996) Role of rheologic factors in patients with acute central retinal vein occlusion. Ophthalmology 103:80–86

    PubMed  CAS  Google Scholar 

  17. Peduzzi M, Debbia A, Guerrieri F, Bolzani R (1986) Abnormal blood rheology in retinal vein occlusion. A preliminary report. Graefes Arch Clin Exp Ophthalmol 224:83–85

    Article  PubMed  CAS  Google Scholar 

  18. Remky A, Arend O, Jung F, Kiesewetter H, Reim M, Wolf S (1996) Haemorheology in patients with branch retinal vein occlusion with and without risk factors. Graefes Arch Clin Exp Ophthalmol 234(Suppl 1):S8–S12

    Article  PubMed  Google Scholar 

  19. Chabanel A, Glacet-Bernard A, Lelong F, Taccoen A, Coscas G, Samama MM (1990) Increased red blood cell aggregation in retinal vein occlusion. Br J Haematol 75:127–131

    Article  PubMed  CAS  Google Scholar 

  20. Glacet-Bernard A, Chabanel A, Lelong F, Samama MM, Coscas G (1994) Elevated erythrocyte aggregation in patients with central retinal vein occlusion and without conventional risk factors. Ophthalmology 101:1483–1487

    PubMed  CAS  Google Scholar 

  21. Lip PL, Blann AD, Jones AF, Lip GY (1998) Abnormalities in haemorheological factors and lipoprotein (a) in retinal vascular occlusion: implications for increased vascular risk. Eye 12:245–251

    PubMed  Google Scholar 

  22. Lowe GD (1987) Blood rheology in general medicine and surgery. Baillières Clin Haematol 1:827–861

    Article  PubMed  CAS  Google Scholar 

  23. McGrath MA, Wechsler F, Hunyor AB, Penny R (1978) Systemic factors contributory to retinal vein occlusion. Arch Intern Med 138:216–220

    Article  PubMed  CAS  Google Scholar 

  24. Peduzzi M, Codeluppi L, Poggi M, Baraldi P (1983) Abnormal blood viscosity and erythrocyte deformability in retinal vein occlusion [letter]. Am J Ophthalmol 96:399–400

    PubMed  CAS  Google Scholar 

  25. Ring CP, Pearson TC, Sanders MD, Wetherley-Mein G (1976) Viscosity and retinal vein thrombosis. Br J Ophthalmol 60:397–410

    Article  PubMed  CAS  Google Scholar 

  26. Trope GE, Lowe GD, McArdle BM, Douglas JT, Forbes CD, Prentice CM, Foulds WS (1983) Abnormal blood viscosity and haemostasis in long-standing retinal vein occlusion. Br J Ophthalmol 67:137–142

    Article  PubMed  CAS  Google Scholar 

  27. Sofi F, Mannini L, Marcucci R, Bolli P, Sodi A, Giambene B, Menchini U, Gensini GF, Abbate R, Prisco D (2007) Role of haemorheological factors in patients with retinal vein occlusion. Thromb Haemost 98:1215–1219

    PubMed  CAS  Google Scholar 

  28. Hansen LL, Wiek J, Schade M, Muller-Stolzenburg N, Wiederholt M (1989) Effect and compatibility of isovolaemic haemodilution in the treatment of ischaemic and non-ischaemic central retinal vein occlusion. Ophthalmologica 199:90–99

    Article  PubMed  CAS  Google Scholar 

  29. Wolf S, Arend O, Bertram B, Remky A, Schulte K, Wald KJ, Reim M (1994) Hemodilution therapy in central retinal vein occlusion. 1-year results of a prospective randomized study. Graefes Arch Clin Exp Ophthalmol 232:33–39

    Article  PubMed  CAS  Google Scholar 

  30. Chen HC, Wiek J, Gupta A, Luckie A, Kohner EM (1998) Effect of isovolaemic haemodilution on visual outcome in branch retinal vein occlusion. Br J Ophthalmol 82:162–167

    Article  PubMed  CAS  Google Scholar 

  31. Hansen LL, Wiek J, Wiederholt M (1989) A randomised prospective study of treatment of non-ischaemic central retinal vein occlusion by isovolaemic haemodilution. Br J Ophthalmol 73:895–899

    Article  PubMed  CAS  Google Scholar 

  32. Wiek J, Schade M, Wiederholt M, Arntz HR, Hansen LL (1990) Haemorheological changes in patients with retinal vein occlusion after isovolaemic haemodilution. Br J Ophthalmol 74:665–669

    Article  PubMed  CAS  Google Scholar 

  33. Glacet-Bernard A, Zourdani A, Milhoub M, Maraqua N, Coscas G, Soubrane G (2001) Effect of isovolemic hemodilution in central retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 239:909–914

    Article  PubMed  CAS  Google Scholar 

  34. Peduzzi M, Debbia A, Stacca R, Torlai F, Guerrieri F (1987) Central retinal vein occlusion, effect of isovolemic hemodilution as an adjunctive therapy. In: Brancato R, Coscas G, Lumbroso B (eds) Retinal diseases 2. Kugler and Ghedini, Amsterdam, pp 89–96

    Google Scholar 

  35. Tranquart F, Arsene S, Aubert-Urena AS, Desbois I, Audrerie C, Rossazza C, Pourcelot L (1998) Doppler assessment of hemodynamic changes after hemodilution in retinal vein occlusion. J Clin Ultrasound 26:119–124

    Article  PubMed  CAS  Google Scholar 

  36. Mohamed Q, McIntosh RL, Saw SM, Wong TY (2007) Interventions for central retinal vein occlusion: an evidence-based systematic review. Ophthalmology 114(507–519):524

    Google Scholar 

  37. Donati G, Mavrakanas N, Pournaras CJ (2009) Isovolumic hemodilution in the management of the acute phase of central retinal vein occlusion: a pilot study. J Fr Ophtalmol 32:750–756

    Article  PubMed  CAS  Google Scholar 

  38. Douat J, Ancele E, Cournot M, Pagot-Mathis V, Mathis A, Quintyn JC (2007) Treatment of central retinal vein occlusion by isovolemic hemodilution. J Fr Ophtalmol 30:1007–1012

    Article  PubMed  CAS  Google Scholar 

  39. Poullin P, Lefevre P (2008) Therapeutic erythrocytapheresis: technical aspects and clinical applications. Rev Méd Interne 29:290–296

    Article  PubMed  CAS  Google Scholar 

  40. Mansour AM, Walsh JB, Goldberger S, Henkind P (1992) Role of diabetes mellitus on the natural history of central retinal vein occlusion. Ophthalmologica 204:57–62

    Article  PubMed  CAS  Google Scholar 

  41. Wolf S, Arend O, Bertram B, Schulte K, Kaufhold F, Teping C, Reim M (1991) Hemodilution in patients with central retinal vein thrombosis. A placebo-controlled randomized study. Fortschr Ophthalmol 88:35–43

    PubMed  CAS  Google Scholar 

  42. Hansen LL, Danisevskis P, Arntz HR, Hovener G, Wiederholt M (1985) A randomised prospective study on treatment of central retinal vein occlusion by isovolaemic haemodilution and photocoagulation. Br J Ophthalmol 69:108–116

    Article  PubMed  CAS  Google Scholar 

  43. Poupard P, Eledjam JJ, Dupeyron G, Saissi G, Bloise L, Arnaud B, d’Athis F (1986) Role of acute normovolemic hemodilution in treating retinal venous occlusions. Ann Fr Anesth Rèanim 5:229–233

    PubMed  CAS  Google Scholar 

  44. Luckie AP, Wroblewski JJ, Hamilton P, Bird AC, Sanders M, Slater N, Green W (1996) A randomised prospective study of outpatient haemodilution for central retinal vein obstruction. Aust N Z J Ophtalmol 24:223–232

    Article  CAS  Google Scholar 

  45. Dhalluin JF, Glacet-Bernard A, Lelong F, Coscas G, Soubrane G (1998) Traitement par hémodilution isovolémique des occlusions de la veine centrale de la rétine récentes. Ophtalmologie 12:442–445

    Google Scholar 

  46. Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jacques ML, Jiao J, Li XY, Whitcup SM (2010) Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 117(1134–1146):e1133

    Google Scholar 

  47. Brown DM, Campochiaro PA, Singh RP, Li Z, Gray S, Saroj N, Rundle AC, Rubio RG, Murahashi WY (2010) Ranibizumab for macular edema following central retinal vein occlusion: 6-month primary end point results of a phase III study. Ophthalmology 117:1124–1133, e1121

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

This study was conducted in eight ophthalmological centers in France, and the co-authors acknowledge the other clinical investigators: Michel Paques (Paris), Bernard Riddings (Marseille), Audrey Feldmann (Lyon), Frederic Rouberol (Lyon), Frederic Galland (Marseille), Pascale Poullin (Marseille), Patrice Lefevre (Marseille), Olivier Hequet (Lyon).

Author information

Authors and Affiliations

  1. Department of Ophthalmology, University Paris XII, Intercommunal and Henri-Mondor hospitals, Créteil, France

    Agnès Glacet-Bernard, Gabriel Coscas, Gisèle Soubrane & Eric Souied

  2. Department of Clinical Biotherapy, University Paris VI, Pitié-Salpétrière Hospital, Paris, France

    Marielle Atassi

  3. Department of Ophthalmology, University Paris VI, Pitié-Salpétrière Hospital, Paris, France

    Christine Fardeau

  4. Department of Ophthalmology, University of Grenoble, Grenoble, France

    Jean-Paul Romanet & Matthieu Tonini

  5. Department of Ophthalmology, La Timone Hospital, Marseille, France

    John Conrath

  6. Department of Ophthalmology, University Hospital of Lyon, Lyon, France

    Philippe Denis

  7. Rabelais Ophthalmic Center, Lyon, France

    Martine Mauget-Faÿsse

  8. Service OPH, Hôpital intercommunal, 40 avenue de Verdun, 94000, Créteil, France

    Agnès Glacet-Bernard

Authors
  1. Agnès Glacet-Bernard
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marielle Atassi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Christine Fardeau
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jean-Paul Romanet
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Matthieu Tonini
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. John Conrath
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Philippe Denis
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Martine Mauget-Faÿsse
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Gabriel Coscas
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Gisèle Soubrane
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Eric Souied
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Agnès Glacet-Bernard.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Glacet-Bernard, A., Atassi, M., Fardeau, C. et al. Hemodilution therapy using automated erythrocytapheresis in central retinal vein occlusion: results of a multicenter randomized controlled study. Graefes Arch Clin Exp Ophthalmol 249, 505–512 (2011). https://doi.org/10.1007/s00417-010-1532-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-010-1532-5

Keywords

Search

Navigation